N

NeuBase Therapeutics Inc
F:O7PA

Watchlist Manager
NeuBase Therapeutics Inc
F:O7PA
Watchlist
Price: 0.159 EUR -3.64% Market Closed
Market Cap: 107.5m EUR

NeuBase Therapeutics Inc
Other

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

NeuBase Therapeutics Inc
Other Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other CAGR 3Y CAGR 5Y CAGR 10Y
N
NeuBase Therapeutics Inc
F:O7PA
Other
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Other
$47m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Other
-$6.5B
CAGR 3-Years
-244%
CAGR 5-Years
-115%
CAGR 10-Years
-8%
Amgen Inc
NASDAQ:AMGN
Other
-$9.6B
CAGR 3-Years
-380%
CAGR 5-Years
-174%
CAGR 10-Years
-31%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other
-$371.2m
CAGR 3-Years
-30%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other
-$276.6m
CAGR 3-Years
31%
CAGR 5-Years
19%
CAGR 10-Years
4%
No Stocks Found

NeuBase Therapeutics Inc
Glance View

Market Cap
107.5m EUR
Industry
Biotechnology

NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 33 full-time employees. The firm is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.

O7PA Intrinsic Value
Not Available
N

See Also

What is NeuBase Therapeutics Inc's Other?
Other
0 USD

Based on the financial report for Sep 30, 2023, NeuBase Therapeutics Inc's Other amounts to 0 USD.

Back to Top